KKKaichi Kaneko

Kaichi Kaneko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaichi Kaneko has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Toshihiro Nanki

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    8 shared publications
  • Makoto Kaburaki

    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan

    7 shared publications
  • Shinichi Kawai

    Department of Inflammation and Pain Control Research, School of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-ku, Tokyo, 143-8540, Japan

    7 shared publications
  • Shinichi Kawai

    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo 143-8541, Japan

    7 shared publications
  • Daiki Sakai

    Division of Rheumatology, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan

    6 shared publications
  • Hirahito Endo

    6 shared publications

Latest Publications

  • Fatal Disseminated Herpes Zoster With Varicella‐Zoster Virus Pneumonia Despite Two‐Dose Recombinant Zoster Vaccination in an Immunosuppressed Patient

    by Katsuya Konishi, Fumihito Abe, Hiroki Wakabayashi, Eisuke Tanaka, Daiki Sakai, Ai Nishida, Kaichi Kaneko, Tetsuya Higuchi

  • Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial

    by Mai Kawazoe, Shotaro Masuoka, Kaichi Kaneko, Zento Yamada, Karin Furukawa, Eri Watanabe, Keiko Koshiba, Soichi Yamada, Sei Muraoka, Hiroshi Sato, et al.

    Summary The efficacy of romosozumab (ROMO) in treating glucocorticoid-induced osteoporosis remains unclear. This randomized clinical trial demonstrated that in patients initiating glucocorticoid therapy, a treatment regimen of 12 months of ROMO followed by 24 months of denosumab (DMAb) was effective compared to either 36 months of DMAb or bisphosphonate monotherapy. Purpose The efficacy of romosozumab (ROMO), an antibody against sclerostin—an inhibitor of Wnt signaling—in the treatment of glucocorticoid-induced osteoporosis remains uncertain, particularly regarding the sequential use of ROMO and denosumab (DMAb). This study aimed to compare the long-term efficacy of 12 months of ROMO followed by 24 months of DMAb (ROMO-DMAb) to 36 months of DMAb or bisphosphonates (BP) alone. Methods Patients with rheumatic diseases who had not previously received osteoporosis drugs and were newly treated with prednisolone ≥ 15 mg/day were randomly assigned to receive ROMO (ROMO-DMAb group), DMAb, or risedronate. Over a 36-month period, we measured bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip every 6 months. Results Thirty-nine patients (median [interquartile ranges] age 72.0 [67.3 – 78.8] years; 69.2% women; prednisolone dose 20.0 [15.0 – 50.0] mg/day) were enrolled. The median percent change in lumbar spine BMD from baseline at 36 months was greatest in the ROMO-DMAb group (ROMO-DMAb; 11.3 [6.8 – 13.8] %, DMAb; 9.4 [4.7 – 13.5] %, BP; 2.1 [-1.3 – 6.8] %). The changes in the femoral neck and total hip were similar between the ROMO-DMAb and DMAb groups, and the increases were much smaller than that in the lumbar spine. Serum levels of total type I procollagen-N-propeptide and tartrate-resistant acid phosphatase-5b decreased in all groups from month 3. Conclusion Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy.


  • Open Access

    Amikacin liposomal inhalation suspension versus injectable streptomycin in patients with refractory pulmonary Mycobacterium avium complex disease: A single-center, retrospective cohort study

    by Hiroki Wakabayashi, Kaichi Kaneko, Yusuke Irie, Daiki Sakai, Yasuo Matsuzawa

    Amikacin liposomal inhalation suspension (ALIS) and injectable streptomycin (SM) are aminoglycosides used in addition to guideline-based therapy (GBT) in patients with Mycobacterium avium complex lung disease (MAC-LD). However, no studies have compared the efficacy of ALIS and injectable SM in patients with refractory MAC-LD. The current study aimed to retrospectively compare the sputum culture conversion rates and the treatment continuation probability of ALIS and injectable SM in patients with refractory MAC-LD. This study included patients with refractory MAC-LD who were diagnosed with MAC-LD at the Department of Respiratory Medicine at Toho University Medical Center Sakura Hospital from April 2010 to May 2023, and who could not achieve negative sputum culture conversion after GBT for at least 6 months resulting in new treatment with ALIS or injectable SM. The medical records of the patients were retrospectively reviewed. Then, the sputum culture conversion rates up to 6 months and the treatment continuation probability up to 6 months between patients receiving ALIS and those receiving injectable SM were compared. Twenty-three patients with MAC-LD were eligible for present study. Eleven patients were treated with ALIS and 12 with injectable SM. Four (36%) patients treated with ALIS and 2 (17%) with injectable SM achieved negative sputum culture conversion, but there was no statistically significant difference between 2 groups ( P = .37). The continuation probability up to 6 months of the patients treated with ALIS was significantly higher than that of patients treated with injectable SM (two-tailed log-rank test hazard ratio: 0.058, 95% confidence interval: 0.018–0.185, P = .0001). The most common cause of injectable SM discontinuation was hospital visit difficulty. ALIS and injectable SM had similar sputum culture conversion rates. However, the former had a higher continuation probability than the latter.

  • Open Access

    Differentiating respiratory syncytial virus pneumonia from interstitial lung disease associated with systemic sclerosis: A case report

    by Hiroki Wakabayashi, Kaichi Kaneko, Eisuke Tanaka, Ryogo Ohashi, Kensuke Namba, Misa Iwayanagi, Hiromasa Sakurai, Yusuke Irie, Daiki Sakai, Kenta Takashima, et al.

    Rationale: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in older adults. In systemic sclerosis, interstitial lung disease is a frequent, serious complication requiring immunosuppressive therapy. Differentiating RSV pneumonia from systemic sclerosis-associated interstitial lung disease (SSc-ILD) is essential for appropriate management and to avoid initiating immunosuppressive agents that may be harmful in cases of RSV pneumonia. Patient concerns: An 85-year-old woman with limited cutaneous systemic sclerosis and dementia presented with a 1-week history of nonproductive cough and fever. Diagnoses: Chest computed tomography (CT) showed bilateral consolidations, bronchial wall thickening, and mucus plugs, suggesting airway infection. However, both respiratory symptoms and CT findings worsened, and sputum and blood cultures remained negative. To differentiate SSc-ILD from viral infection, multiplex PCR testing (FilmArray) of a pharyngeal swab was performed, detecting RSV and confirming RSV pneumonia. Interventions: The patient was initially treated with intravenous ceftriaxone, then given prednisolone at 0.6 mg/kg/d after RSV was diagnosed. Outcomes: Her respiratory symptoms and CT findings improved, and she was discharged on day 16 with tapering corticosteroids. Lessons: Multiplex PCR is useful for detecting RSV pneumonia in patients with autoimmune diseases. Clinicians should be aware that RSV infection can occur in these patients and should consider RSV pneumonia as an important differential diagnosis of SSc-ILD.

  • Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study

    by Daiki Sakai, Kaichi Kaneko, Karin Furukawa, Mai Kawazoe, Yasuo Matsuzawa, Toshihiro Nanki

    Mepolizumab (MPZ) is an anti-interleukin-5 monoclonal antibody used to treat eosinophilic granulomatosis with polyangiitis (EGPA). This study aimed to compare the efficacy of MPZ and conventional treatment (CT) for EGPA after maintenance therapy initiation. In this retrospective, observational study, patients diagnosed with EGPA meeting these criteria were included: prednisolone ≤ 20 mg/day, Birmingham Vasculitis Activity Score (BVAS) < 10, and MPZ or new CT initiation ≥ 6 months after initial treatment were included (MPZ: n = 16; CT: n = 16). BVAS, relapse-free survival, absolute eosinophil count, cumulative glucocorticoids (GC) dose, and GC toxicity index (GTI) were evaluated for up to 12 months. Multivariable linear regression for BVAS and logistic regression for relapse at 12 months were performed, adjusting for age, gender, disease duration, and baseline eosinophil count. In the MPZ group, BVAS at 12 months significantly decreased, while BVAS tended to be lower in the MPZ than in the CT group at 12 months. Participants achieving BVAS = 0 significantly increased in the MPZ group at 12 months. Relapse rates tended to be lower in the MPZ group. Absolute eosinophil counts decreased in the MPZ compared with the CT group from 1 to 12 months. Cumulative GC dose and GTI significantly decreased in the MPZ group vs. CT group. In multivariable analyses, the use of MPZ was suggestive of lower BVAS and lower odds of relapse at 12 months compared with CT, although these differences were not statistically significant. MPZ could be a potential treatment option for reducing GC or improving residual symptoms in patients with EGPA.


  • Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases

    by Karin Furukawa, Kaichi Kaneko, Mai Kawazoe, Kotaro Shikano, Takahiko Sugihara, Toshihiro Nanki

    Objective: The long-term effectiveness of denosumab, an antireceptor activator of nuclear factor-κB ligand monoclonal antibody, for increasing bone mineral density (BMD) and reducing fracture risk in postmenopausal women with osteoporosis (OP) has been demonstrated; however, the long-term effectiveness and safety in patients with rheumatic diseases (RDs) remain unclear. Therefore, the present study investigated the long-term effectiveness and safety of denosumab for OP in patients with RDs. Methods: This retrospective study included patients who received denosumab between August 2013 and August 2022. We evaluated BMD at the lumbar spine for up to 7 years and at the femur for up to 3 years. The effects of glucocorticoid (GC) usage, age, and renal function on BMD in patients receiving denosumab were assessed. The retention rate and adverse events were also evaluated. Results: One hundred sixty-five patients with RDs were enrolled (median age 66.5 years, 92.1% female, 68.5% receiving GC therapy). Lumbar spine BMD significantly increased over 7 years (P < 0.001), whereas femoral neck, trochanter, and total hip BMD significantly increased for up to 3 years (P < 0.001). Lumbar spine BMD significantly increased regardless of GC dose, age, or renal dysfunction. The retention rate of denosumab at 7 years was 68.1%. The most common serious adverse event was infection. Two cases of osteonecrosis of the jaw and 10 new fractures were observed during treatment with denosumab. Conclusion: The present study suggests that the long-term use of denosumab is an effective and generally safe option for increasing BMD in patients with RDs.


  • Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

    by Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, et al.

    Context: Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP. Objective: To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP. Methods: Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months. Results: Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1-12.4]%, DMAb: 3.3 [1.5-6.2]%, BP: −0.4 [−3.4-1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N-terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups. Conclusion: Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Clinical trial number: UMIN000037239


  • Open Access

    Changes in Arterial Stiffness Monitored Using the Cardio-Ankle Vascular Index in Patients with Rheumatic Disease Receiving Initial Glucocorticoid Therapy: A Clinical Pilot Study

    by Kaichi Kaneko, Daiki Sakai, Shuji Sato, Toshio Kinoshita, Kazuhiro Shimizu

    Systemic inflammatory rheumatic diseases predispose to premature birth, accelerated atherosclerosis, and increased cardiovascular disease (CVD). While glucocorticoids (GCs) are used in various rheumatic diseases, and the associations between GC excess and increased prevalence of CVD complications are well established, the mechanisms underlying GCs’ role in atheroma development are unclear. We conducted an observational study to address GC therapy’s effect on arterial stiffness using the cardio-ankle vascular index (CAVI) in patients with rheumatic diseases. Twenty-eight patients with rheumatic disease received initial GC therapy with prednisolone at doses ranging from 20 to 60 mg/d. CAVI was examined at baseline and 3 and 6 months after GC therapy. Changes in CAVI and inflammatory parameters were evaluated. GC therapy increased the mean CAVI after 3 months but decreased it to pretreatment levels after 6 months. The mean CAVI substantially decreased with GC treatment in patients <65 years but increased in patients ≥65 years. Alterations in CAVI during the 6-month GC treatment negatively correlated with the lymphocyte-to-monocyte ratio (LMR) at baseline. Conversely, no correlation was observed between alterations in CAVI values and conventional inflammatory markers (C-reactive protein and erythrocyte sedimentation rate). Multivariate analysis of factors related to changes in CAVI highlighted young age, high prednisolone dosage, and LMR at baseline. GC temporarily exacerbates but eventually improves arterial stiffness in rheumatic diseases. Particularly in young patients, GC may improve arterial stiffness by reducing inflammation. Therefore, the LMR before GC therapy in rheumatic diseases may be a potential predictor of arterial stiffness.


  • Open Access

    Minocycline-induced vasculitis

    by Rika Kurata, Nobuyuki Hiruta, Kaichi Kaneko


  • Open Access

    Serum IgG4-negative IgG4-related disease with a cardiac mass: A case report

    by Kensuke Namba, Daiki Sakai, Hiroshi Mikamo, Yuta Sugizaki, Yoshiya Sugiura, Nobuyuki Hiruta, Yasuo Matsuzawa, Kaichi Kaneko

    Rationale: Although IgG4-related disease (IgG4-RD) can affect various organs, its association with a cardiac mass is exceptionally rare. Here, we report a case of a woman with IgG4-RD and a cardiac mass and discuss 10 similar cases reported previously. Patient concerns: A 65-year-old woman was referred to our hospital for chest discomfort and back pain. Diagnoses: In accordance with the 2019 ACR/EULAR diagnostic criteria for IgG4-RD, she was diagnosed with IgG4-RD based on dense lymphocytic infiltration on histopathology, IgG/IgG4-positive cell ratio 10/hpf IgG4-positive cells on immunostaining, and paraspinal zone soft tissue lesions in the chest. Interventions: An external pacemaker was implanted for the complete atrioventricular block on the electrocardiogram. After the diagnosis of IgG4-RD, she was treated with glucocorticoids and rituximab. Outcomes: She remains under observation without disease recurrence. Lessons: IgG4-RD are usually treated with glucocorticoids; however, in cases of a cardiac mass, life-threatening complications may occur and surgery is often needed. Combination therapy with glucocorticoids and rituximab may be effective even in patients with IgG4-RD and cardiac mass, which may avoid the need of invasive treatments, such as surgery.